Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spending Bill Addresses Conflict Waivers, Sunscreen Monograph

This article was originally published in The Tan Sheet

Executive Summary

FDA will be required to publicly disclose the rationale behind any advisory committee conflict of interest waivers under an amendment to the Senate version of the agency's spending bill
Advertisement

Related Content

EU Sheds Light On Recommended Sunscreen Labeling Options
EU Sheds Light On Recommended Sunscreen Labeling Options
EU Sheds Light On Recommended Sunscreen Labeling Options
EU sunscreen guidance
EU sunscreen guidance
Schering-Plough, J&J Named Defendants In Class-Action Suit
Schering-Plough, J&J Named Defendants In Class-Action Suit
Schering-Plough, J&J Named Defendants In Class-Action Suit
CAERS Funding Flat While Drug Safety Increases In FDA Spending Bill
CAERS Funding Flat While Drug Safety Increases In FDA Spending Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS098680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel